Lupin gets USFDA nod for generic medication

Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic medication to treat seizures.

The company has received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules in the US, the drug firm said in a statement.

The product is a generic equivalent of Supernus Pharmaceuticals, Inc.'s Trokendi XR extended-release capsules, it added.

Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.

As per IQVIA MAT, Topiramate extended-release capsules had an estimated annual sale of USD 253 million in the US.

Shares of Lupin ended 1.04 per cent lower at Rs 1,798 apiece on the BSE.